Lab Med Online.  2020 Oct;10(4):330-333. 10.47429/lmo.2020.10.4.330.

Elimination of Anti-CD47 Interference in Pretransfusion Testing by Multiple Platelet Alloadsorption: A Case Report

• Lee H
• Kim YJ
• Kim JS
• Yang JJ
• Hwang SH
• Oh HB
• Ko DH

• KMID: 2512274
• DOI: http://doi.org/10.47429/lmo.2020.10.4.330

Abstract

Hu5F9-G4, an immunoglobulin 4 (IgG4) monoclonal humanized antibody targeting CD47, is under active clinical trials as a novel immunotherapeutic for hematologic and solid malignancies and can cause pretransfusion testing interference. In this study, we demonstrate our first experience of Hu5F9-G4 interference with serologic testing and mitigate this interference through multiple platelet alloadsorption. A 69-year-old woman with a history of ureter cancer presented with anemia. On routine blood group typing, the patient showed strong agglutination (4+) with anti-A, A, and B cells. Unexpectedly, antibody screening and identification showed panreactivity to all panel cells, although the autocontrol result was negative. Medical records revealed that she was enrolled in an anti-CD47 clinical trial. To eliminate interference by the drug, we attempted alloadsorption using pooled platelets that were prepared from segments of random single donor platelets. After seven alloadsorption sessions using pooled allogeneic platelets, the ABO discrepancy and panreactivity was resolved. To our knowledge, this is the first demonstration of anti-CD47 interference elimination in Korea.

Keyword

Hu5F9-G4; Anti-CD47; Pretransfusion test; Interference; Alloadsorption

Reference

1. Branch DR. 2019; Immunotherapy: the good, the bad, the ugly, and the really ugly. Transfusion. 59:437–40. DOI: 10.1111/trf.15142. PMID: 30727039.

2. Brierley CK, Staves J, Roberts C, Johnson H, Vyas P, Goodnough LT, et al. 2019; The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia. Transfusion. 59:2248–54. DOI: 10.1111/trf.15397. PMID: 31183877.

3. Mei Z, Wool GD. Snyder EL, Gehrie EA, editors. 2019. Impact of novel monoclonal antibody therapeutics on blood bank pretransfusion testing. Transfusion medicine. Elsevier;Philadelphia, PA: p. 797–812. DOI: 10.1016/j.hoc.2019.05.007. PMID: 31466605.

4. Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. 2019; First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. J Clin Oncol. 37:946–53. DOI: 10.1200/JCO.18.02018. PMID: 30811285. PMCID: PMC7186585.

5. Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, et al. 2018; CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma. N Engl J Med. 379:1711–21. DOI: 10.1056/NEJMoa1807315. PMID: 30380386.

6. Velliquette RW, Aeschlimann J, Kirkegaard J, Shakarian G, Lomas-Francis C, Westhoff CM. 2019; Monoclonal anti-CD47 interference in red cell and platelet testing. Transfusion. 59:730–7. DOI: 10.1111/trf.15033. PMID: 30516833.

7. Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C. 2018; Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep. 45:2935–40. DOI: 10.1007/s11033-018-4427-x. PMID: 30311129.

8. Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. 2015; Resolving the daratumumab interference with blood compatibility testing. Transfusion. 55:1545–54. DOI: 10.1111/trf.13069. PMID: 25764134. PMCID: PMC7484995.

9. 2017. Ministry of Health and Welfare, Committee of New Health Technology Assessment, New Health Technology Assessment Report HTA-2017-26, RHCE·Other blood group gene [PCR-hybridization]: Ministry of Health and Welfare, Committee of New Health Technology Assessment.